(AOF) – Poxel announces that as of September 30, 2023, its cash and cash equivalents amounted to 5.3 million euros. The biotech specialist in innovative treatments against metabolic diseases, including non-alcoholic steatohepatitis (NASH), specifies that by including the entire drawdown of the equity financing line set up with Iris, its financing horizon runs until ‘at the end of the 2nd quarter of 2025. Poxel achieved a turnover of 1.61 million euros for the nine months ended September 30, compared to 286,000 euros a year earlier.
“We continue our active discussions with investors and potential partners, and are mobilized to obtain additional financing to advance our rare disease strategy and launch Phase II proof of concept (POC) studies in the ALD,” said Thomas Kuhn, Managing Director of Poxel.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.